Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

More than 1,000,000 patients are being treated with Dupixent globally.1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...